FDA/CDC

FDA issues MiniMed600 insulin pump recall


 

Medtronic is recalling certain MiniMed600 insulin pumps as part of a class I recall, the most serious kind of recall, because of a potentially fatal risk of incorrect dosing, according to a Food and Drug Administration MedWatch release.

FDA icon Wikimedia Commons/FitzColinGerald/ Creative Commons License

A class I recall such as this indicates that there is reasonable probability that using a defective pump will cause serious adverse health consequences or death, the agency said in the recall notice. It said the company has received more than 26,000 complaints regarding this problem and is aware of 2,175 injuries and 1 death so far. In all, 322,005 devices have been recalled.

If the pumps in question – Model 630G (distributed September 2016 to October 2019) and 670G (June 2017 to August 2019) – have broken or missing retainer rings, the insulin cartridge can end up loose in the reservoir compartment, which can lead to incorrect dosing and therefore potentially to hyperglycemia or hypoglycemia, according to the statement.

Model 630G was approved by the FDA in August 2016, and the 670G in September that same year.

On Nov. 21, 2019, Medtronic advised patients with type 1 diabetes who use the pumps to:

  • Examine the retainer ring to see if it is loose, broken, or missing.
  • Stop using the pump if the reservoir does not lock correctly or if the retainer ring is loose, damaged, or missing. Patients should contact Medtronic for a replacement pump and follow their doctor’s recommendations and perform manual insulin injections.
  • Continue using the pump if the reservoir locks in place correctly.
  • Check pump and retainer ring if the pump is dropped by accident, and stop use if it is damaged.
  • Check the pump and retainer ring every set change to verify the reservoir is locked correctly.

More information regarding this recall, including how to contact Medtronic Technical Support, can be found on the FDA website.

Recommended Reading

What will it take to lower the cost of insulin in the United States?
MDedge Internal Medicine
Barbers have role in encouraging diabetes screening in black men
MDedge Internal Medicine
FDA okays triple-combo pill for type 2 diabetes
MDedge Internal Medicine
Gestational diabetes: Treatment controversy rages on
MDedge Internal Medicine
Menopause hormone therapy found to delay type 2 diabetes
MDedge Internal Medicine
Noninjectable modes of insulin delivery coming of age
MDedge Internal Medicine
NASH ‘an epidemic of the 21st century’
MDedge Internal Medicine
How much exercise is needed for maximum heart benefit?
MDedge Internal Medicine
FDA not recommending recalls of diabetes drug metformin
MDedge Internal Medicine
Data emerging to support personalized nutrition in oncology
MDedge Internal Medicine